From the last three recent company announcement before Percheron Therapeutics to present at BIO 2024:
https://convention.bio.org/sessions/percheron-therapeutics-limited 1)Percheron granted US patent for DMD -
"The granting of the patent by the US Patent and Trademark Office precludes other companies from commercialising ATL1102 in DMD in the US until at least 2039....may thereafter be eligible for a patent term extension of up to 5 years...Substantially increases the value of ATL1102..." 2)Preliminary results of 9 Month Toxicology Study of ATL1102 -
".. the results appear to be broadly confirmatory so far " Note: Just to refresh our memory, why this is so important to Percheron Therapeutics...Please listen to Dr Charmaine Gittleson (latest part of the interview : "...It opens up the opportunity to use that data we would generate from the toxicology study to pursue other indications in the US should the organisation wish to do that, so this is a really
important step in the overall program for Antisense. "
VIDEO From the Wilson Advisory research report (Getting the FDA monkey off their back dated 14-11-2022) - "Lifting of the partial hold on the US IND is key to opening dialogue with the FDA around future ATL1102 registration pathways.
Having one key market "locked" for ATL1102's advancement was holding back investor interest in our view."
3)Percheron Therapeutics wraps up recruitment for DMD study -
"With the study now fully enrolled, we expect to have initial topline data in December 2024 ." I came across this article, thought I'd share it here.
https://www.mpo-mag.com/issues/2022-02-02/view_columns/escaping-the-valley-of-death-the-funding-process-for-biotechnology-companies/ I believe we're at/near the value of inflection point:
Stay positive and may the force be with you!!
Value Inflection Point Success in early human safety studies, also known as Phase I or Phase I/IIa trials, may provide a new source of tailwind to push forward, but typically this is not enough to elevate depressed valuations because significant risks remain with larger, longer, more expensive trials still to come. The majority of investors and strategic partners wait for results from the next step—Phase II/IIB clinical trials—before committing significant capital Positive Phase II/IIB clinical trial data triggers a value inflection point that may benefit from two parallel forces. First, the investor base may expand to include a large new class of institutional investors that invest in late-stage biotech companies. Increasing demand for and higher trading volume of company stock will increase share price as new investors build a position in the company. Second, large strategic players are always on the hunt for promising products to add to their portfolio. Typically, strategics look for positive Phase II/IIB data as the entry point for partnership or acquisition, as the risk profile has been substantially reduced. With a limited number of viable technologies touting robust Phase II/IIB data, competition may be intense for high-quality product candidates, further driving up value. L
ate-Stage Development and Market Entry Now that the company has successfully navigated the valley of death, management can focus on late-stage trials and prepare for commercialization. The company should be well-positioned to secure additional capital or a strategic partner to advance through the final clinical trials to market approval and deliver on its promise to both patients and shareholders. 
